Company intelligence / Profile preview
1ST Biotherapeutics
Yongin-si, Gyeonggi-do, South Korea1stbio.com ↗
- Ownership
- Private
- Employees
- ~24
- Development stage
- Other
01
Overview
Currently conducting Phase 1/2 clinical trials for FB-849 (HPK1 inhibitor) for advanced solid tumors, and Phase 1 trials for FB-101 and FB-418 for ALS
- Therapeutic areas
- OncologyRare DiseasesNeurology
- Modalities
- Small molecule drugsAntibody drug conjugates (ADC)TIL therapyDiagnostic radiopharmaceuticals
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
The Michael J. Fox Foundation's LITE ProgramMerck (for KEYTRUDA combination study)
Beyond the preview
Go deeper on 1ST Biotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 1ST Biotherapeutics.